Kaleido Biosciences to Present During the Goldman Sachs 41st Annual Global Healthcare Conference

On June 4, 2020 Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, reported that Alison Lawton, President and Chief Executive Officer, will participate in a fireside chat during the virtual Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 11:20 a.m. ET (Press release, Kaleido Biosciences, JUN 4, 2020, View Source [SID1234560833]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available in the Investors & Media section of Kaleido’s website at View Source An archived replay will be accessible for 90 days following the event.

NuVasive, Inc. Announces Full Exercise Of Option By Initial Purchasers To Purchase Additional 1.00% Convertible Senior Notes Due 2023

On June 4, 2020 NuVasive, Inc. (NASDAQ: NUVA) reported that it closed the issuance of an additional $50.0 million in aggregate principal amount of the 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes"), pursuant to the exercise in full of the initial purchasers’ option to purchase such additional notes (the "Option Notes") in connection with the previously announced Convertible Notes offering that closed on June 1, 2020 (Press release, NuVasive, JUN 4, 2020, View Source;301070982.html [SID1234560850]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Option Notes have the same terms as the Convertible Notes. The Option Notes were issued under the same Indenture as the Convertible Notes dated as of June 1, 2020 between the Company and Wilmington Trust, National Association, as trustee, which terms are described in the Company’s Current Report on Form 8-K filed on June 1, 2020.

The sale of the Option Notes to the initial purchasers settled on June 4, 2020, subject to customary closing conditions, and resulted in approximately $48.6 million in net proceeds to NuVasive (in addition to the previously announced net proceeds of $387.5 million from the initial closing of the offering of the Convertible Notes on June 1, 2020) after deducting fees and estimated offering expenses payable by NuVasive.

In addition, in connection with the issuance of the Option Notes, NuVasive entered into privately negotiated additional convertible note hedge transactions and additional warrant transactions with certain dealers, including affiliates of certain of the initial purchasers of the Convertible Notes and other financial institutions (the "Option Counterparties"). The additional convertible note hedge transactions and the additional warrant transactions are on substantially similar terms as the base convertible note hedge transactions and base warrant transactions entered into on May 27, 2020 with the Option Counterparties.

NuVasive intends to use approximately $2.5 million of the net proceeds from the offering of the Option Notes to pay the cost of the additional convertible note hedge transactions (after such cost is partially offset by the proceeds to NuVasive from the additional warrant transactions). NuVasive intends to use the remaining net proceeds for working capital and other general corporate purposes, which may include potential mergers and acquisitions, to refinance indebtedness and for repurchases of outstanding Convertible Senior Notes due 2021 (the "2021 Notes"). Any repurchase of the 2021 Notes could have the effect of raising or maintaining the market price of NuVasive’s common stock above levels that would otherwise have prevailed, or preventing or retarding a decline in the market price of NuVasive’s common stock, and thereby impacting the trading price of the Convertible Notes.

The offering of the Option Notes is only being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the Option Notes nor any shares of NuVasive’s common stock issuable upon conversion of the Option Notes have been or are expected to be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

Ireland’s Shorla nabs $8.3M to bring improved cancer meds to the U.S.

On June 3, 2020 Shorla Pharma reported that picking up $8.3 million to push its programs through regulatory approval and build up its technical and commercial operations ahead of its first drug launch in 2021 (Press release, Shorla Pharma, JUN 3, 2020, View Source [SID1234560786]). The company will hire "key personnel" in Ireland, Cunningham told FierceBiotech. And with the U.S. as its first market, part of the funds will go toward setting up an outpost to take care of business development and regulatory and commercialization activities stateside.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Dublin-based company is working on three programs, all of which are improvements on established drugs, which may have a difficult-to-use formulation, not treat certain types of cancer very well or be in limited supply. Cunningham and Ryan didn’t disclose what the drugs are, beyond saying they are all "established active substances" that have been "proven from a safety and efficacy perspective."

Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA™ Platform at the Jefferies Virtual Global Healthcare Conference

On June 3, 2020 Maverick Therapeutics, Inc., a private biopharmaceutical company pioneering conditionally active bispecific T cell targeted immunotherapies, reported pipeline updates for its robust set of Conditional Bispecific Redirected Activation (COBRATM) programs at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020 (Press release, Maverick Therapeutics, JUN 3, 2020, View Source [SID1234560802]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By nature of its elegant and innovative design, the COBRATM platform is the most mature bispecific T cell engaging platform in its class that can safely target solid tumors with highly specific and potent activity. COBRA molecules are prodrugs selected to bind to specific targets, which may be expressed in both tumor and healthy tissue. However, COBRAs are engineered to take advantage of the tumor’s unique microenvironment for T cell activation; triggering T cell mediated killing only at the site of the tumor while sparing damage to patients’ healthy tissues.

"As we continue to advance our pipeline, we look forward to initiating the clinical development of our lead first-in-class COBRA programs, MVC-101 and MVC-280, both of which have generated promising pre-clinical data designed to validate the COBRA mechanism of action and be predictive of translation to patients. Our pipeline reflects our single focus on developing potent and conditionally active T cell engaging therapies for solid tumor cancers. Beyond our two lead programs, we have also generated compelling in vivo data for two additional COBRA molecules," said Jim Scibetta, Chief Executive Officer, Maverick Therapeutics. "The first patient who is safely and effectively treated for a solid tumor cancer with any form of T cell therapy, whether CAR T cell therapy or redirected T cell engagers like our COBRAs, will serve as a major breakthrough in the field of cancer immunotherapy. For us at Maverick, this is an incredibly important and humbling mission."

"Although evidence of anti-tumor activity has been observed in patients with solid cancers, the full potential of T cell engaging therapies against solid tumor cancers continues to be hindered by unacceptable toxicity," said Jim Vasselli, M.D., Senior Vice President, Clinical Development, Maverick Therapeutics. "Underpinning the pre-clinical development of COBRA technology is Maverick’s commitment to using gold standard in vivo and in vitro models to maximize our understanding of the molecules. We are encouraged by the early results generated by these first two programs and are excited to continue development towards the clinic."

MVC-101 Is a Highly Potent COBRA Targeting Tumors that Express EGFR

Maverick Therapeutics’ lead program candidate, MVC-101, is a proprietary COBRA molecule designed to target Epidermal Growth Factor Receptor (EGFR), a protein expressed on both malignant and healthy tissues. MVC-101 regressed established human tumors in several preclinical models. Exposures of MVC-101 at efficacious relative to tolerated doses in safety studies demonstrates an increased therapeutic index compared to standard T cell engagers. MVC-101 is designed to be a universal solution for patients with EGFR expressing solid tumor cancers. EGFR is expressed on a wide range of solid tumor cancers, including but not limited to colorectal, head & neck, renal, pancreatic, cervical and non small cell lung cancers. Maverick expects to initiate a Phase 1 trial in Q1 2021.

MVC-280 Is a Highly Potent COBRA Targeting Tumors that Express B7H3

Maverick Therapeutics’ second program candidate, MVC-280, is a proprietary COBRA molecule designed to target B7H3 (CD276). B7H3 is expressed in a broad range of malignant and healthy tissues, similar to EGFR. MVC-280 regressed established tumors in several preclinical models. It is cross-reactive to its target protein expressed on mouse tissues, creating an opportunity to measure both efficacy and relative safety in the same preclinical model and use that data to calculate a therapeutic index. MVC-280 is designed to be a universal solution for patients with B7H3 expressing solid tumor cancers. B7H3 is expressed on a wide range of solid tumor cancers, including but not limited to prostate, renal, triple negative breast, head & neck, ovarian and urothelial cancers. Maverick expects to initiate a Phase 1 trial in H2 2021.

About the COBRATM Therapeutics Platform

Maverick Therapeutics’ COBRATM platform is the most mature conditionally active bispecific T cell engaging platform designed to safely target a broad range of solid tumors with highly specific and potent activity while limiting on-target toxicities in normal tissues. By nature of its highly innovative design, the COBRA platform reflects a novel approach to T cell engaging immunotherapies where T cell activation and resulting cell killing only take place where it is needed – in tumors. This unique design delivers the long sought after trifecta in cancer care; high specificity, high potency and reduced toxicity.

$2 million SBIR grant fast-tracks cancer drug platform technology, which aims to better treat relapse

On June 3, 2020 Purdue University reported that Acute myeloid leukemia (AML), an aggressive blood cancer, is one of the most lethal cancers. More than 19,000 new cases are diagnosed a year, and more than 11,000 people a year die from it, according to the American Cancer Society (Press release, KinaRx, JUN 3, 2020, View Source,-which-aims-to-better-treat-relapse.html [SID1234560885]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A $1,999,998 SBIR Phase I/II grant from the National Cancer Institute to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform aimed at treating relapse for AML and other diseases.

"We are ready to take our technology to the next level and potentially help people who are dealing with aggressive and deadly diseases that offer few treatment options, particularly for relapse patients," said Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry.

KinaRx was founded by Sintim, who is its chief scientific officer, along with M. Javad Aman, Rena Lapidus, Ashkan Emadi, Frederick Holtsberg and Joe O’Neill.

The compounds under development by KinaRx were developed using Sintim’s platform that makes complex drug molecules rapidly using bioinformatics, multi-component compound synthesis and the understanding of disease biology.

KinaRx has licensed drug compounds through the Purdue Research Foundation Office of Technology Commercialization, which is now housed in the Convergence Center for Innovation and Collaboration in Discovery Park District, adjacent to the Purdue campus.

"These compounds have shown promise in treating people who have a recurrence of AML and now we want to do further testing and move into clinical trials," said Sintim, who is a member of the Purdue University Center for Cancer Research and the Purdue Institute for Drug Discovery.

About 30 percent of AML patients have a mutation caused by a kinase called FLT3, which makes the leukemia more aggressive. Although a few FLT3 inhibitors have already been approved in the clinic, patients can relapse due to mutations in the FLT3 protein, which cause drug resistance. KinaRx is commercializing a series of new compounds that inhibit mutant FLT3 kinases, especially mutant versions that are resistant to current FDA-approved FLT3 inhibitors such as gilteritinib. These compounds were developed by researchers in Sintim’s lab at Purdue.

The researchers are looking for partners to continue testing and developing their technology. For more information on other opportunities related to the technology, contact Sintim at [email protected].